birb 796 has been researched along with tanespimycin in 2 studies
| Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (tanespimycin) | Trials (tanespimycin) | Recent Studies (post-2010) (tanespimycin) |
|---|---|---|---|---|---|
| 137 | 5 | 80 | 921 | 39 | 496 |
| Protein | Taxonomy | birb 796 (IC50) | tanespimycin (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.004 | |
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 3 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 7.65 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.031 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.9391 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.5124 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 3 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.031 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.496 | |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | 0.78 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H | 1 |
| Asantewaa, G; Ciesla, JH; Dewhurst, S; Harris, IS; Leach, J; Lutz, MM; Monaghan, M; Munger, J; Raymonda, MH; Schafer, XL; Smorodintsev-Schiller, LA; Takimoto, T | 1 |
2 other study(ies) available for birb 796 and tanespimycin
| Article | Year |
|---|---|
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2007 |
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Benzoquinones; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Synergism; High-Throughput Screening Assays; Humans; Lactams, Macrocyclic; Lapatinib; Naphthalenes; Phenylurea Compounds; Pyrazoles; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |